Rare disease

FDA
#FDA #IntraBio #Rare disease #Zevra Therapeutics

FDA approves two treatments for Niemann-Pick Disease

This week, the US Food and Drug Administration (FDA) has approved both Zevra Therapeutics’ Miplyffa (arimoclomol) and IntraBio’s Aqneursa (levacetylleucine) for Neimann-Pick disease, type C (NPC). Miplyffa, in combination with the enzyme inhibitor miglustat, is approved to treat neurological symptoms associated with NPC in adults and children two years of… Read More

#News #Regulatory

#Cardiometabolic diseases #NanoVation Therapeutics #Novo Nordisk #Partnership #Rare disease

Novo Nordisk and NanoVation enter multi-target partnership

Novo Nordisk and NanoVation Therapeutics have announced a multi-year partnership to advance the development of novel genetic medicines targeting cardiometabolic and rare diseases. The partnership will combine NanoVation Therapeutics’ long-circulating lipid nanoparticle (lcLNP) technology for RNA delivery to cells outside of the liver with Novo Nordisk’s expertise in cardiometabolic and… Read More

#Business & Investment #News

Human eye
#Gene therapy #Genetics / genomics #Ophthalmology #Rare disease #University of Florida

Gene therapy restores vision in first-of-its-kind trial

A gene therapy developed by University of Florida scientists restored useful vision to most patients with rare condition Leber congenital amaurosis type I (LCA1) in a small trial. Patients who received the highest dose of the gene therapy saw up to a 10,000-fold improvement in their… Read More

#News #Trending News

Human liver
#European Medicines Agency #Liver disease #Orphan drugs #Rare disease #SeaBeLife

Orphan drug prevents cell death in acute liver failure

Biotechnology company SeaBeLife has secured orphan drug designation (ODD) from the European Medicines Agency (EMA) for its drug candidate SBL01 in the treatment of acute liver failure (ALF). ALF occurs when the liver suddenly loses its ability to function in a person without a pre-existing liver… Read More

#News

#Cereno Scientific #European Commission #Hypertension #Orphan drugs #Rare disease

EU orphan designation for pulmonary hypertension drug

The European Commission has granted orphan medicinal product designation (OMPD) to Cereno Scientific’s lead drug candidate CS1 for pulmonary arterial hypertension (PAH). CS1 is an HDAC inhibitor that works through epigenetic modulation, being developed to offer improved quality of life and prolonged life for patients with PAH. Companies that obtain… Read More

#News #Regulatory

Genomics
#Clinical trials #Genetics / genomics #Interview #Personalised medicine #Rare disease

Sitting down with… Dr Patrick Short, Sano Genetics

DDW's Diana Spencer caught up with Dr Patrick Short, CEO and Co-Founder, Sano Genetics, about the challenges facing personalised medicine development and his own personal experience of genetic conditions. DS: You and your co-founders met at the University of Cambridge. Can you tell us about the founding of the company?… Read More

#Exclusive Content

Child with retinoblastoma
#FDA #Oncology #Paediatrics #Rare disease #Theriva Biologics

Retinoblastoma therapy gets FDA rare paediatric drug designation

Theriva Biologics’ VCN-01 for retinoblastoma has been granted rare paediatric drug designation (RPDD) by the US Food and Drug Administration (FDA). The FDA grants RPDD for rare diseases (fewer than 200,000 affected persons in the United States) that are serious and life-threatening and primarily affect children ages 18 years or… Read More

#News #Regulatory

#Antisense Oligonucleotides (ASOs) #Collaboration #Evotec #Partnership #Rare disease #SynaptixBio

SynaptixBio and Evotec extend rare disease therapies partnership

SynaptixBio and Evotec have announced they are extending their partnership to find further candidate drugs to treat H-ABC, the most severe form of TUBB4A leukodystrophy. The drug research was originally carried out by the Children’s Hospital of Philadelphia (CHOP), the world’s leading centre for leukodystrophy research,… Read More

#News

Stamp of approval
#Chiesi #Dermatology #Plant-based #Rare disease #Scottish Medicines Consortium (SMC)

Two rare disease therapies approved in Scotland

The Scottish Medicines Consortium (SMC) has published final advice on two rare disease therapies. Elfabrio (pegunigalsidase alfa), a novel enzyme replacement therapy (ERT), has been approved as a treatment option for Fabry disease in adults. Also, birch bark extract gel has been approved as a treatment option for junctional and… Read More

#News #Regulatory

CRISPR Cas9
#CRISPR #Genetics / genomics #Intellia Therapeutics #Phase I trial #Rare disease

Evidence supports redosing with an in vivo CRISPR-based therapy

Intellia Therapeutics has shared the first-ever clinical data demonstrating the potential for redosing with an investigational in vivo CRISPR-based therapy. The data from the ongoing Phase I study of NTLA-2001, a single-dose treatment in development for transthyretin (ATTR) amyloidosis, were presented at the Peripheral Nerve Society Annual Meeting. Read More

#News

The Hospital for Sick Children (SickKids) in Toronto, Canada
#Gene therapy #Genetics / genomics #Neurodegenerative disorders #Rare disease

Gene therapy halts progression of rare genetic condition

The findings from a single-patient gene therapy trial in Canada show promise in halting the progression of spastic paraplegia type 50 (SPG50). SPG50 is an ultra-rare progressive neurodegenerative disorder that causes developmental delays, speech impairment, seizures, progressive paralysis of all four limbs, and is typically fatal… Read More

#News #Trending News

#Ageing #Mergers and acquisitions #Rare disease #Sentynl Therapeutics

Sentynl buys treatment for rare ageing disease

Biopharmaceutical company Sentynl Therapeutics has acquired Eiger Biopharmaceuticals’ approved treatment for the rare disease progeria. Progeria, also known as Hutchinson-Gilford progeria syndrome (HGPS) and processing-deficient progeroid laminopathies (PDPL), in young people 12 months of age and older, are ultra-rare, fatal, genetic premature ageing diseases that accelerate mortality in young patients. Eiger’s… Read More

#Business & Investment #News

Child having a hearing test
#Gene mutation #Gene therapy #Genetic diseases #Hearing Loss #Paediatrics #Rare disease

Gene therapy cures profound genetic deafness within 24 weeks

The investigational gene therapy DB-OTO improved hearing to normal levels in a child (dosed at 11 months of age) within 24 weeks, according to trial data presented at the American Society of Gene and Cell Therapy (ASGCT) annual conference. Initial hearing improvements have also been observed… Read More

#News #Trending News

#Aardvark Therapeutics #Financing #Investment #Obesity #Orphan drugs #Rare disease

Funding of $85 million secured for Prader-Willi Syndrome drug

Aardvark Therapeutics has announced an $85 million oversubscribed Series C financing. The funding will be used to complete the clinical trials required for regulatory approval of Aardvark’s lead asset, ARD-101, for the treatment of hyperphagia in patients with Prader-Willi Syndrome (PWS), as well as to demonstrate ARD-101’s complementary mechanism of… Read More

#Business & Investment #News

#Allogene Therapeutics #allogeneic cell therapies #Biologics #Biotech #Cancer Research Horizons #Cancer vaccine #CAR-T #Cell therapy #Clinical trials #Drug discovery #Financing #Funding #LifeArc #Oncology #Rare disease #Research and development #Seed funding #Start-ups #University of Dundee #University of Oxford

New DDW Highlights episode: 8 May 2024

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  The ongoing innovation and development in the drug discovery sector relies on a number… Read More

#News

#Allogene Therapeutics #allogeneic cell therapies #Biologics #Biotech #Cancer Research Horizons #Cancer vaccine #CAR-T #Cell therapy #Clinical trials #Drug discovery #Financing #Funding #LifeArc #Oncology #Rare disease #Research and development #Seed funding #Start-ups #University of Dundee #University of Oxford

This week in drug discovery (29 April – 3 May) 

News round-up for 29 April – 3 May by DDW Multimedia Editor Megan Thomas. The ongoing innovation and development in the drug discovery sector relies on a number of moving parts, one of which is financial support and backing. Whether it is successful seed funding or dedicated investment,… Read More

#News